Clinical Trial Update: Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis. [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study evaluating two formulations of imiquimod cream 3.75% in patients with actinic keratosis; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Imiquimod Cream 3.75% (Imiquimod)

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Actinic Keratosis | Phase 1 | Status: COMPLETED